...clinical need, scientific evidence and the technology landscape. That is the approach we have been developing at FRESCI within the EIC Transition Coati-X project. For patients undergoing haemodialysis or long-term cancer treatment, central vascular access devices can be essential to care. At the same time, infection and thrombosis remain important complications, with consequences for patients, treatment continuity and healthcare systems. Our 2025 white paper, Safer Devices

LLMs can speed up evidence work. But if you can’t reproduce and audit what the model changed, your “AI-enabled” pipeline can become a credibility liability.

The Imperative of Market Viability/Economic sustainability In the rapidly evolving field of scientific research, particularly in...

In the ever-evolving field of health research, there lies a complex interplay between technological standardization, market acceptance,...